Prime Diagnostic Imaging

primemri.com

Prime Diagnostic Imaging in the Dallas-Fort Worth area provides world-class diagnostic imaging services utilizing state-of-the-art imaging tools. In our quest to become the leading national provider of diagnostic and screening services, we have created strategic partnerships by joint venturing with referring physicians in every community. Prime Diagnostic Imaging specializes in delivery of Magnetic Resonance Imaging (MRI), Computerized Axial Tomography (CAT or CT), Nuclear Medicine, Ultrasound and Pain Management.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

HILLSTREAM BIOPHARMA TO ANNOUNCE COLLABORATING WITH SAPIEN BIOSCIENCES

Hillstream | June 30, 2022

news image

Hillstream BioPharma, Inc., a U.S.-based biotechnology company developing novel therapeutic candidates targeting ferroptosis for cancer treatment, announced a collaboration with an Indian pioneer biobank and peonalized medicine company that leverages Saarum Innovation's global life sciences research expertise, Sapien Biosciences. The collaboration is aimed at assessing the compatibility of HSB-1216 with immune checkpoint inhibitors. HSB-1216, Hillstream’s most advanced c...

Read More

Cell and Gene Therapy

DYADIC ANNOUNCES A NIIMBL CORONAVIRUS GRANT UNDER THE WHITE HOUSE’S AMERICAN RESCUE PLAN

Dyadic International, Inc. | December 23, 2021

news image

Dyadic International, Inc. a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve access to biologic vaccines and drugs at flexible commercial scales, announced it is the recipient of one of thirty-two project grants awarded by the National Institute for Innovation in Manufacturing Biopharmaceuticals funded through the White House’s American Rescue ...

Read More

Medical

ENTOPSIS EXPLORING STRATEGIC ALTERNATIVES FOR ITS OPSISDX™ PLATFORM

Berkery, Noyes & Co. | October 08, 2021

news image

Entopsis, Inc., the developer of an unbiased approach to diagnostics using bio-molecular signatures with a focus on oncology, announced that it has engaged Berkery Noyes & Co. as its financial advisor to assist the company in pursuing strategic alternatives for their OpsisDxTM platform. OpsisDxTM is a urine-based technology platform that shifts the focus away from conventional RNA and DNA approaches, offering a highly sensitive and specific diagnostic test for the detection of...

Read More

MedTech, Industry Outlook

VAXXINITY DEMONSTRATES TARGET ENGAGEMENT OF TOXIC ALPHA-SYNUCLEIN IN PARKINSON’S PATIENTS

Globenewswire | July 18, 2023

news image

Vaxxinity, Inc. a U.S. company pioneering the development of a new class of medicines, announced new data from a Phase 1 clinical trial demonstrating that antibodies derived from its investigational immunotherapeutic for Parkinson’s disease (PD), UB-312, slows seeding of alpha-synuclein (aSyn) in cerebrospinal fluid (CSF) of patients with PD as demonstrated using multiple target engagement assays. These data signify that UB-312 has established clear target engagement in PD patient CS...

Read More
news image

Medical

HILLSTREAM BIOPHARMA TO ANNOUNCE COLLABORATING WITH SAPIEN BIOSCIENCES

Hillstream | June 30, 2022

Hillstream BioPharma, Inc., a U.S.-based biotechnology company developing novel therapeutic candidates targeting ferroptosis for cancer treatment, announced a collaboration with an Indian pioneer biobank and peonalized medicine company that leverages Saarum Innovation's global life sciences research expertise, Sapien Biosciences. The collaboration is aimed at assessing the compatibility of HSB-1216 with immune checkpoint inhibitors. HSB-1216, Hillstream’s most advanced c...

Read More
news image

Cell and Gene Therapy

DYADIC ANNOUNCES A NIIMBL CORONAVIRUS GRANT UNDER THE WHITE HOUSE’S AMERICAN RESCUE PLAN

Dyadic International, Inc. | December 23, 2021

Dyadic International, Inc. a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve access to biologic vaccines and drugs at flexible commercial scales, announced it is the recipient of one of thirty-two project grants awarded by the National Institute for Innovation in Manufacturing Biopharmaceuticals funded through the White House’s American Rescue ...

Read More
news image

Medical

ENTOPSIS EXPLORING STRATEGIC ALTERNATIVES FOR ITS OPSISDX™ PLATFORM

Berkery, Noyes & Co. | October 08, 2021

Entopsis, Inc., the developer of an unbiased approach to diagnostics using bio-molecular signatures with a focus on oncology, announced that it has engaged Berkery Noyes & Co. as its financial advisor to assist the company in pursuing strategic alternatives for their OpsisDxTM platform. OpsisDxTM is a urine-based technology platform that shifts the focus away from conventional RNA and DNA approaches, offering a highly sensitive and specific diagnostic test for the detection of...

Read More
news image

MedTech, Industry Outlook

VAXXINITY DEMONSTRATES TARGET ENGAGEMENT OF TOXIC ALPHA-SYNUCLEIN IN PARKINSON’S PATIENTS

Globenewswire | July 18, 2023

Vaxxinity, Inc. a U.S. company pioneering the development of a new class of medicines, announced new data from a Phase 1 clinical trial demonstrating that antibodies derived from its investigational immunotherapeutic for Parkinson’s disease (PD), UB-312, slows seeding of alpha-synuclein (aSyn) in cerebrospinal fluid (CSF) of patients with PD as demonstrated using multiple target engagement assays. These data signify that UB-312 has established clear target engagement in PD patient CS...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us